<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02570087</url>
  </required_header>
  <id_info>
    <org_study_id>CTOHFrEF</org_study_id>
    <nct_id>NCT02570087</nct_id>
  </id_info>
  <brief_title>Benefits of CTO-PCI in Selected Cases With HFrEF (CTOHFrEF)</brief_title>
  <acronym>CTOHFrEF</acronym>
  <official_title>Benefits of Chronic Total Coronary Occlusion Percutaneous Intervention in Patients With Chronic Heart Failure and Reduced Ejection Fraction.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Clinic of Barcelona</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Clinic of Barcelona</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators studied the effect of CTO-PCI on left ventricular function and clinical
      parameters in patients with HFrEF.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Observational studies have shown that chronic total coronary occlusion percutaneous
      intervention (CTO-PCI) improves angina, left ventricular ejection fraction (LVEF), and
      survival. None of these studies aimed to assess the benefits in populations with heart
      failure with reduced ejection fraction (HFrEF). The investigators studied the effect of
      CTO-PCI on left ventricular function and clinical parameters in patients with HFrEF.

      Using cardiac magnetic resonance (CMR), the investigators studied 29 patients with HFrEF and
      evidence of viability and/or ischemia in the territory supplied by an occluded vessel who
      were successfully treated with CTO-PCI. Non-CTO PCI was also performed in patients with
      multi-vessel disease, . Imaging parameters, clinical status, and brain natriuretic peptide
      (BNP) levels were evaluated before and six months after CTO-PCI.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2011</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">August 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Left ventricular ejection fraction (%)</measure>
    <time_frame>6 months</time_frame>
    <description>Evaluate changes in left ventricular function by cardiac magnetic resonance imaging 6 months after CTO PCI</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>NYHA functional class (I-V)</measure>
    <time_frame>6 months</time_frame>
    <description>Evaluate changes in NYHA functional class 6 months after CTO PCI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial ischemia</measure>
    <time_frame>6 months</time_frame>
    <description>Evaluate changes in number of segments with induced ischemia by cardiac magnetic resonance imaging 6 months after CTO PCI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brain Natriuretic Peptide (pg/ml)</measure>
    <time_frame>6 months</time_frame>
    <description>Evaluate changes in brain natriuretic peptide 6 months after CTO PCI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of in-hospital CTO PCI major adverse events</measure>
    <time_frame>6 months</time_frame>
    <description>Safety evaluation of CTO PCI in patients with HFrEF (periprocedural mortality, periprocedural STEMI or need for urgent myocardial revascularization surgery)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">39</enrollment>
  <condition>Chronic Total Occlusion Vessel</condition>
  <arm_group>
    <arm_group_label>Successful CTO PCI</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Successful chronic total coronary occlusion percutaneous intervention (CTO-PCI)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Unsuccessful CTO PCI</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Unsuccessful chronic total coronary occlusion percutaneous intervention (CTO-PCI)</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>chronic total coronary occlusion percutaneous intervention</intervention_name>
    <description>Percutaneous intervention of chronic total coronary occlusion with stent implantation</description>
    <arm_group_label>Successful CTO PCI</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  At least one chronic total coronary occlusion

          -  LVEF ≤40% by CMR

          -  Evidence of myocardial viability and/or ischemia in at least two contiguous segments
             subtended by the occluded vessel.

        Exclusion Criteria:

          -  Women of childbearing age or pregnant

          -  Claustrophobia

          -  Admission to hospital within the previous 90 days due to decompensated heart failure,
             myocardial infarction or unstable angina.

          -  Severe valvulopathy

          -  Pacemaker or implantable cardioverter defibrillator

          -  Indication for coronary artery bypass surgery

          -  Heart transplantation waiting list

          -  Follow-up not feasible

          -  Life expectancy shorter than 12 months.

          -  Iodine contrast or gadolinium allergy

          -  Aspirin or clopidogrel allergy

          -  Asthma

          -  NYHA IV class

          -  Liver cirrosis

          -  Noncompliance with medical treatment

          -  Chronic kidney disease with serum creatinine levels ≥ 2.5 mg/dl or glomerular
             filtration rate ≤30 ml/min/1.73m2

          -  Evidence of active bleeding

          -  High risk of bleeding

          -  CTO distal vessel not visible through collateral circulation

          -  CTO distal vessel diameter &lt;2mm

          -  Absence of acceptable vascular access
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 25, 2015</study_first_submitted>
  <study_first_submitted_qc>October 5, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 7, 2015</study_first_posted>
  <last_update_submitted>October 5, 2015</last_update_submitted>
  <last_update_submitted_qc>October 5, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 7, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Clinic of Barcelona</investigator_affiliation>
    <investigator_full_name>Montserrat Cardona</investigator_full_name>
    <investigator_title>Consultant</investigator_title>
  </responsible_party>
  <keyword>Coronary ChronicTotal Occlusion</keyword>
  <keyword>Coronary Angioplasty</keyword>
  <keyword>Reduced Ejection Fraction</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

